Françoise S.
- Country
- Belgium
- Department
- Pediatric gastroenterology
Research Overview
- A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)
- HepaStem Long-Term Safety Registry – Registry for Patients who have been administered HepaStem
- Evaluation of Ozanimod Efficacy and Safety in Pediatric Patients with Moderate to Severe Crohn's Disease Unresponsive to Conventional Therapy
Data & Insights
Has run more than one trial at 45 of 82 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating pediatric inflammatory bowel disease, with particular emphasis on both Crohn's disease and ulcerative colitis in their moderate to severe forms.
- Pediatric Crohn's Disease Therapeutics
- Ulcerative Colitis Treatment Strategies
- Inflammatory Disease Assessment
Their work encompasses evaluating novel therapeutic approaches for young patients with inadequate response to conventional treatments.
Innovative Biological Therapies
The investigator focuses on advancing treatment options through biological therapies, including studies with IL-23 inhibitors and various immunomodulators for pediatric patients.
- Monoclonal Antibody Treatments
- Immunomodulator Therapy
- Long-term Treatment Outcomes
Their research evaluates both intravenous induction and subcutaneous maintenance treatment protocols.
Regenerative Medicine
The investigator explores cell-based therapies and their applications in treating various hepatic conditions, including urea cycle disorders and Crigler-Najjar syndrome.
- Stem Cell Therapy Applications
- Liver Disease Treatment
- Long-term Safety Monitoring
Their work includes assessment of innovative cellular therapies for fibroinflammatory liver diseases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.